By Daniella Parra
Recordati, an international pharmaceutical company said its consolidated net revenue rose 12% to €1.3 billion in the first half of 2025.
Rare Diseases revenue was €515.7 million for the first half of 2025, up 29.2% as compared with the first half of 2024, it said.
“The strong performance in the first half of 2025 reflects solid execution across the business, with robust revenue growth and disciplined cost management,” Rob Koremans, CEO of Recordati said. “The licensing and supply agreement with Amarin to commercialize Vazkepa in Europe reinforces our commitment to the SPC business and further strengthens our core Cardiovascular franchise.”
READ MORE
ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer
Never Miss our Weekly Highlights HERE
